Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy
Launched by JOHNSON & JOHNSON ENTERPRISE INNOVATION INC. · Jan 28, 2022
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
Robotic-assisted navigational bronchoscopy (RANB) improves accuracy of lesion localization and diagnostic yield of the peripheral pulmonary nodule (PPN) biopsy compared to conventional flexible bronchoscopy. Needle based confocal laser endomicroscopy (nCLE) allows real-time microstructural imaging of lung nodule tissues at the needle tip. The study is designed to evaluate the safety and feasibility of utilizing nCLE during RANB biopsy procedure to optimize needle position and diagnostic accuracy, as well as reduce or replace the need for additional imaging tools such as radial endobronchial...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 22 years at signing of informed consent form (ICF).
- • Undergoing standard-of-care RANB for a solid lung nodule, which is considered to be at intermediate- to high-risk for malignancy as determined by the investigator per the institution's standard of care.
- • ICF signed before any study procedures are initiated.
- Exclusion Criteria:
- • Medical contraindication to bronchoscopy under general anesthesia, or lack of physical fitness to undergo bronchoscopy under general anesthesia or to follow the study processes, as assessed by the investigator.
- • Presence of uncorrectable bleeding disorders, or anticoagulation/anti-platelet aggregation therapy that cannot be withheld for an appropriate interval prior to the procedure, as defined per the institution's standard of care.
- • Medical devices interfering with electro-magnetic navigation, including but not limited to pacemakers.
- • Subjects who have a target lesion that shows endobronchial involvement on chest CT.
- • Participation in any other clinical trial within 30 days of enrollment, that would interfere with this study.
- • Known hypersensitivity to fluorescein sodium or any other ingredients in the fluorescein product.
- • Planned surgical resection at the time of bronchoscopy
- • Female subjects who are pregnant or nursing at the time of the procedure.
About Johnson & Johnson Enterprise Innovation Inc.
Johnson & Johnson Enterprise Innovation Inc. is a leading global healthcare company dedicated to advancing the science of health through innovative solutions. As a subsidiary of Johnson & Johnson, it focuses on harnessing cutting-edge technologies and collaborative strategies to drive breakthroughs in medical research and product development. The organization emphasizes patient-centric approaches, aiming to enhance health outcomes across diverse therapeutic areas. By fostering partnerships and leveraging its extensive expertise, Johnson & Johnson Enterprise Innovation Inc. is committed to delivering transformative healthcare solutions that address unmet medical needs and improve quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Concord, California, United States
Altoona, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Balaji Laxmanan, MD
Study Director
Johnson & Johnson Enterprise Innovation Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials